Merck touts expensive new COVID drug while dismissing cheap ivermectin

Read more on this subject: Drugs and Medications
News Story Source: https://www.wnd.com, By Art Moore
The announcement Friday by Merck that it plans to apply for emergency approval of a new experimental oral antiviral treatment for COVID-19 is of particular interest to many physicians who have been hindered or completely blocked from treating their COVID patients off-label with an FDA-approved drug that already is produced by the pharmaceutical giant.

Merck is the producer of ivermectin, which has been shown to be effective in an least 65 controlled studies and 32 randomized controlled trials to fight COVID-19 as a preventative and early- and late-stage treatment. Studies have demonstrated its ability to inhibit the replication of SARS-CoV-2 as well as its strong anti-inflammatory properties.

Yet, as Rep. Louie Gohmert pointed out in a commentary this week, the "government alphabet agencies, the medical industrial complex, and their willing accomplices in the media" have made ivermectin "the latest naughty word which will get you censored on social m
Read More or Make a Comment

Bookmark the permalink.

Comments are closed.